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Laboratory of Integrative and Systems Physiology (LISP), Ecole Polytechnique Fédérale de Lausanne, CH-1015 Lausanne, SwitzerlandBile acids (BAs) are amphipathic molecules that facilitate the absorption. The scope of this review is to provide an update on
uptake of lipids, and their levels ﬂuctuate in the intestine as well
as in the blood circulation depending on food intake. Besides
their role in dietary lipid absorption, bile acids function as signal-
ing molecules capable to activate speciﬁc receptors. These BA
receptors are not only important in the regulation of bile acid
synthesis and their metabolism, but also regulate glucose homeo-
stasis, lipid metabolism, and energy expenditure. These processes
are important in diabetes and other facets of the metabolic syn-
drome, which represents a considerable increasing health bur-
den. In addition to the function of the nuclear receptor FXRa in
regulating local effects in the organs of the enterohepatic axis,
increasing evidence points to a crucial role of the G-protein cou-
pled receptor (GPCR) TGR5 in mediating systemic actions of BAs.
Here we discuss the current knowledge on BA receptors, with a
strong focus on the cell membrane receptor TGR5, which emerges
as a valuable target for intervention in metabolic diseases.
 2011 European Association for the Study of the Liver. Published
by Elsevier B.V. All rights reserved.Introduction
BAs are multifunctional in metabolism
Bile acids (BAs) are a component of bile, which also contains phos-
phatidylcholine, bilirubin, and cholesterol as main constituents.
An important physiological role of BAs is to facilitate the uptake
of lipids together with the fat-soluble vitamins A, D, E, and K from
the intestine. BAs facilitate these absorptive processes through
their detergent properties, which allow the emulsiﬁcation of lip-
ids [1]. BAs also play a major role in inﬂuencing the intestinal
microbial ﬂora, as well as in the elimination of cholesterol from
the body [2,3]. More recently, BAs are increasingly being appreci-
ated for their signaling properties to transmit information to cells
and organs concerning the fasting/feeding state thereby regulat-
ing processes ranging from bile acid and lipid metabolism to
glucose and energy homeostasis [4,5]. This is in fact not too
surprising given the central role BAs play in dietary lipidJournal of Hepatology 20
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their pharmaceutical implications to treat metabolic diseases,
such as diabetes and other risk factors of the metabolic syndrome.Signaling pathways activated by BAs
Nuclear receptor signaling pathways
FXR is a nuclear receptor that controls BA homeostasis and trans-
port as outlined (see Textboxes 1–3; [6–33]; Fig. 1). The FXR
cDNA was ﬁrst cloned from both mouse and rat in 1995
[34,35]. Rodents have two FXR family members, FXRa and FXRb.
In humans only FXRa is expressed, although FXRb is still present
in the human genome as a non-expressed pseudogene. FXRa is
most potently activated by conjugated or unconjugated forms
of CDCA with an EC50 in the range of 4.5–10 lM [36–38], while
FXRb in mice is activated by lanosterol, an intermediate of bile
acid synthesis [39].
In addition to FXRa, other nuclear receptors directly activated
by LCA are the pregnane X receptor (PXR) and the vitamin D
receptor (VDR) [40–42] (see Fig. 2). PXR is not only activated by
LCA, but also by certain bile acid precursors, such as 7a-OH-4-
cholesten-3-one [43]. PXR is like FXRa expressed in the liver
and intestine [40,41]. One of the physiological functions of PXR
is to induce phase I detoxiﬁcation metabolism through induction
of CYP3A expression, which explains the ﬁnding that PXR trans-
genic mice are protected against LCA-induced liver toxicity in a
model of cholestasis [40]. Like PXR, VDR plays a role in the detox-
iﬁcation of BAs through upregulation of CYP3A [42]. In addition
to their roles in detoxifying BAs, both nuclear receptors inhibit
BA synthesis. VDR is not expressed in hepatocytes [44]. However,
activation of VDR in the intestine by vitamin D widely inhibits BA
synthesis via the FGF19-CYP7A1 pathway [45], and activation of
PXR with rifampicin, an agonist of human PXR, inhibits BA syn-
thesis through a pathway involving HNF4a [46]. It should be
noted that relative high concentrations of LCA (ranging from 30
to 100 lM) are needed to induce activation of VDR and PXR,
which could raise questions about the physiological relevance
of the direct regulation of their activity by BAs.
Kinase-signaling pathways regulated by BAs
BAs also modulate kinase-signaling pathways, such as the JNK
pathway, which has been demonstrated to be involved in the11 vol. 54 j 1263–1272
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Fig. 1. Simpliﬁed overview of classical bile acid synthesis pathway in mice.
CYP7A1 and CYP8B1 catalyze the ﬁrst and third reaction, respectively. Dotted
lines represent several steps in the synthesis of BAs that involve multiple
enzymes. AKR1D1 is an abbreviation for D4-3-oxosteroid 5b-reductase.
Reviewdownregulation of CYP7A1 [47]. Another study has coupled JNK
activation indirectly to BAs as the mechanism of the FGF19-
FGFR4 signaling pathway to suppress CYP7A1 [48]. In addition
to JNK, also the p38 mitogen activated protein kinases
(p38MAPK), the extracellular signal-regulated kinase (ERK) path-
way, as well as Akt are activated by BAs [49,50]. Although the
precise mechanisms involved are not fully clear, a study has indi-
cated that phosphorylation of ERK1, ERK2, and Akt by BAs is
induced through both radical oxygen species (ROS)-dependent,1264 Journal of Hepatology 2011as well as through GPCR-dependent pathways [50]. The activa-
tion of these phosphorylation cascades by BAs is, besides the sup-
pression of CYP7A1, also involved in the regulation of apoptosis
and cytoprotective effects [49,51]. It is also tempting to speculate
that some of these signaling pathways may be involved in the
enhanced lifespan, observed in yeast exposed to BAs, as yeast
do not express either the nuclear or membrane BA receptors [52].
GPCR signaling pathways modulated by BAs
Most relevant to this review is that BAs also bind andmodulate the
activity of speciﬁc G-protein coupled receptors (GPCRs) (see
Fig. 2). The total GPCR family comprises over 800 receptors, which
are divided into three subgroups [53]. There are currently three
known GPCRs whose activities are modulated by BAs. Based
on their sequence homology, these BA-modulated GPCRs are
classiﬁed in the class A or rhodopsin-like receptor class, which
represents the largest subgroup of GPCRs. BAs are able to modu-
late the activity of the muscarinic receptors (also designated as
acetylcholine receptors) [54,55], and inhibit the activity of the
formyl-peptide receptors (FPRs) [56,57]. FPR receptors have been
described to be expressed in neutrophils and monocytes, and are
activated by N-formyl groups, present on bacterial and mitochon-
drial proteins. This induces cell chemotaxis, believed to direct
phagocytes to sites of tissue damage or infections. It is possible
that the inhibition of activity of these receptors by BAs contributes
to anti-inﬂammatory properties of BAs, as CDCA inhibited FPR-
induced human leukocyte chemotaxis. [58]. The ﬁve muscarinic
receptors (designated M1–M5) regulate numerous physiological
processes by mediating parasympathetic innervation viavol. 54 j 1263–1272
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ute to several diseases, including metabolic diseases [59]. Musca-
rinic receptors are expressed in the central nervous system aswell
as in peripheral organs. For example, theM3muscarinic receptors,
which are predominantly expressed in gastrointestinal tissues,
control smooth-muscle contractility and glandular secretion. Also
the pancreatic b-islet cells express M3 muscarinic receptors, and
induce insulin release during the pre-absorptive phase of feeding
[60]. These data suggest that these receptors could potentially
contribute to a broad range of effects observed by BAs, although
it should be mentioned that high millimolar concentrations of
BAs are necessary to induce activation of muscarinic receptors.
The relevance has not been analyzed so far in humans.
The GPCR that has beenmost studied in relation to BAs is TGR5,
also known as M-BAR, GPBAR, or GPR131. This cell-surface BA
receptor was discovered in 2002 [61], and ﬁrst characterized in
2003 [62]. TGR5 is encoded by a single-exon gene, and its conser-
vation among several vertebrate species underlines the relevanceJournal of Hepatology 2011of this GPCR in vertebrate physiology [61]. Human TGR5 is acti-
vated bymultipleBAs,with LCAbeing themost potent natural ago-
nist with an EC50 of 0.53 lM [61,62]. Next to LCA, other bile acids
that activate TGR5 include conjugated and unconjugated forms
of DCA, CDCA, and CA with an EC50 of 1.0, 4.4, and 7.7 lM, respec-
tively [62]. Human andmouse TGR5 showbasically the same afﬁn-
ity for the different BAs, although certain synthetic TGR5 agonists
reveal a large difference between mouse and human TGR5 with
regard to their efﬁcacy to activate the receptor [63].
The bile acid receptor TGR5
Expression and signaling of TGR5
TGR5 is expressed in many different organs and cells with vary-
ing degrees of expression. For example, high expression levels of
TGR5 have been detected in gallbladder epithelium [64,65] and in
the intestine, mainly in the ileum and colon [61,66]. TGR5 was
also highly expressed in human monocytes as compared to other
human leukocyte subsets examined [62]. In line with these ﬁnd-
ings, rabbit spleen and rabbit alveolar macrophages were also
found to express relatively high levels of TGR5 versus other tis-
sues [62]. TGR5 is detected in several liver cells, including rat
liver sinusoidal endothelial cells, as well as in rat Kupffer cells,
resident macrophages of the liver [67,68]. TGR5 is also expressed
in BAT, skeletal muscle, and selected areas of the central nervous
system [69,70]. Furthermore, TGR5 is ubiquitously expressed in
many more different organs and cells with varying degrees of
expression [62,64].
In resting conditions, GPCRs, including TGR5, are in a so-called
low-afﬁnity state. In response to binding of BAs to the ligand-vol. 54 j 1263–1272 1265
Fig. 2. Representation of signaling pathways that are modulated by BAs. Genomic and non-genomic actions of BAs are mediated by nuclear receptors and G-protein
coupled receptors. The BAs that modulate the activity of the receptor are indicated in the arrow, and are sorted by decreasing potency (top to bottom). Arrows in green
indicate agonistic actions, red indicates antagonistic/inhibitory actions and blue indicates a modulatory effect, either agonistic or antagonistic. Receptors for which only a
limited number of BAs were tested are indicated with dashed arrows. ⁄Only conjugated forms of LCA and DCA are reported to activate the muscarinic receptors.
Reviewbinding pocket of the receptor, a complex is released from TGR5
consisting of G-protein-as, b, and c [53,62]. GDP is subsequently
released from the G-protein and replaced by GTP, leading to dis-
sociation of the G-protein complexes into G-protein-as and bc
dimers. G-protein-as subsequently activates adenylyl cyclase
resulting in the induction of cAMP and activation of protein
kinase A (PKA), which in turn induces further downstream signal-
ing [62] (see Fig. 3). Whether TGR5 may also bind to other G-pro-
teins, which have distinct downstream effector molecules, is still
an open question [53].Fig. 3. Simpliﬁed overview of the TGR5-signaling pathway leading to down-
stream signaling via cAMP induction.
1266 Journal of Hepatology 2011TGR5 in BA homeostasis and metabolism
To explore the biological role of TGR5, several groups have inde-
pendently generated TGR5/ mice [64,66,71]. Interestingly, the
total bile acid pool size in TGR5/ mice was decreased as com-
pared to that of wild-type mice [66], which was also observed
by our laboratory (JA & KS, unpublished data). The cause of the
decreased BA pool in TGR5/ mice is currently unknown, but
appears not to be caused by changed fecal excretion of BAs, which
was similar between TGR5/ and control mice [66].
In addition to changes in the BA pool size, TGR5/ mice fed a
lithogenic diet were protected against cholesterol gallstone for-
mation [72]. Hydrophobic bile salts decrease gallbladder smooth
muscle function potentially via stimulation of TGR5, which could
be a contributing factor in the manifestation of gallstone disease
[73]. Additionally, TGR5 is expressed in human gallbladder epi-
thelial cells and cholangiocytes and was shown to play a role in
bile composition, via the induction of chloride secretion [65,74].
Taken together, the physiological changes observed in mice lack-
ing TGR5 with regard to BA homeostasis, combined with the
expression of TGR5 in human tissues relevant to BA homeostasis
hint toward a role of TGR5 in bile formation and homeostasis in
man [65,74].
Effect of TGR5 on body weight
TGR5 activation induces a signiﬁcant reduction of the body
weight of mice fed a high fat diet. We ﬁrst demonstrated that die-
tary supplementation of BAs signiﬁcantly reduces body weight
gain in C57Bl/6J mice fed a high fat diet [69]. CA administrationvol. 54 j 1263–1272
Table 1. Cellular actions described for TGR5 in different cell types.
Cell type Species  Cellular action References
Macrophages* Rabbit / Rat/namuH noitcudorpenikotycfonoitibihnI [62, 68] 
Enteroendocrine cells esuoM/namuH Secretion of GLP-1 [71, 79] 
Brown adipocytes Mouse  erutidnepxeygreneniesaercnI [69] 
Sketelal muscle cells Human  erutidnepxeygreneniesaercnI [69] 
Sinusoidal endothelial cells Rat esahtnysONlailehtodnefonoitalugeR [67] 
Biliary epithelial cells esuoM noitercesedirolhcfonoitomorP [65]
Astrocytes Rat Generation of ROS [101]
Enteric neurons Mouse  ytilitomlanitsetnifonoisserppusdnaONfoesaeleR [70]
Gallbladder smooth muscle cells noitcnufllecelcsumhtoomsreddalbllagfoesaerceD [73] Mouse
⁄Macrophages include alveolar macrophages, Kupffer cells and THP-1 cells.
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mass and morphology, and reversed 120 days of diet-induced
weight gain within 30 days, without toxicity [69]. The weight
reducing effects were not due to reduced caloric intake, but were
the consequence of enhanced energy expenditure. Using deiodin-
ase 2 (D2)-deﬁcient mice, the effect of CA on energy expenditure
was shown to require the induction of deiodinase 2 (D2) through
a TGR5-cAMP-mediated pathway that was active in murine BAT
and in human skeletal muscle myoblasts. Importantly, this effect
of BAs on energy expenditure was independent of FXR, as the FXR
agonist GW4064, did not increase cAMP levels in BAT, and
increased diet-induced obesity in mice. D2 is able to increase
mitochondrial oxidative phosphorylation and energy expenditure
in brown adipose tissue and muscle via the conversion of inactive
thyroxine (T4) into active 3,5,30-tri-iodothyronine (T3), which
subsequently binds and activates the thyroid hormone receptor,
thereby inducing energy expenditure [69]. It should be men-
tioned that postprandial plasma BA levels of 15 lM are capable
of activating TGR5 [69]. The latter effects were subsequently
conﬁrmed in a study using the semi-synthetic BA, 6-ethyl-
23(S)methyl-cholic acid (6EMCA or INT-777), which acts as a
speciﬁc TGR5, but not FXR, agonist [71].
In agreement with our data, Maruyama et al. observed that
female TGR5/ mice have increased body weight [66]. The latter
effect of TGR5 was already observed in heterozygous female
mice. In agreement with this observation, female TGR5/ mice
had a higher fat content, while the lean body weight was unaf-
fected as compared to wild-type mice. Also the body composition
of the male TGR5/ mice showed a tendency toward increased
fat content [66]. Interestingly, in the TGR5/ mice line that we
have generated in our laboratory, we also observed a signiﬁcant
increase in body weight in males ([71] and KS & JA unpublished
data). These two studies are, however, in contrast to the data of
Vassileva et al. [72], which did not observe an effect on body
weight in the absence of TGR5. This difference may very well
be explained by different diets used, or by other differences in
animal experimental conditions applied in this speciﬁc study.
Furthermore, it needs to be underscored, that the mere absence
of a receptor, as in the TGR5/ mice, should not necessary trans-
late in the opposite phenotype as observed after receptor activa-
tion by exogeneous ligands.
A recent study assessed BA levels in humans with respect to
energy expenditure [75]. In this study, patients suffering fromJournal of Hepatology 2011cirrhosis displaying elevated plasma BA levels and healthy con-
trols were compared with respect to energy expenditure. It was
concluded that no correlations between BA levels and energy
expenditure exist. It should, however, be underlined that themany
symptoms observed in cirrhosis are not controlled, and more
than likely confound the study outcome. A better understanding
of the impact of BA on energy expenditure in humans will require
further studies speciﬁcally designed to address this question.
Effects of TGR5 on glucose metabolism and insulin sensitivity
High circulating levels of BAs have been linked with beneﬁcial
effects on glucose metabolism, such as improved insulin sensitiv-
ity and postprandial glycemic control [76,77]. We have demon-
strated that BAs regulate glucose homeostasis through
activation of TGR5 [78]. In agreement with the report that
TGR5 induces GLP-1 secretion in cultured mouse enteroendocrine
STC-1 cells [79], the semi-synthetic BA, 6-ethyl-23(S)methyl-cho-
lic acid (6EMCA or INT-777), which is a speciﬁc TGR5 agonist,
induces GLP-1 secretion in both STC-1 cells as well as in human
intestinal NCI-H716 cells, and contributes as such to the effects
of TGR5 in glucose homeostasis. Silencing of TGR5 in STC-1 cells
using short hairpin RNA prevented the secretion of GLP-1, illus-
trating the involvement of TGR5 in this response. Although the
mechanism underlying TGR5-induced GLP-1 secretion is not yet
completely established, stimulation of oxidative phosphorylation
may be involved in triggering this process. The resulting increase
in ATP/ADP ratio can subsequently induce membrane depolariza-
tion and Ca2+ mobilization in a way reminiscent to the cascade of
events that precedes insulin release in pancreatic b-cells [71].
Using obese and insulin resistant mouse models, we have shown
that mice with a gain-of-function of TGR5 became more glucose
tolerant, whereas TGR5/ mice showed a delayed glucose clear-
ance compared to their wild-type littermates. This effect was cor-
related with a healthier pancreatic islet phenotype, and is at least
partly explained by the tonic increase of GLP-1 secretion by TGR5
[78]. It was recently reported by Poole et al. that TGR5 is also
expressed in inhibitory motor neurons and modulates intestinal
motility [70]. This effect of TGR5 could be related to GLP-1 induc-
tion, which is also known to inhibit intestinal motility [80]. In
apparent contrast to these observations are the ﬁndings in a
recent study with independently generated TGR5/ mice, dem-
onstrating that female and male chow fed TGR5/ mice showvol. 54 j 1263–1272 1267
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improved insulin sensitivity [72]. However, it was also shown in
this study that male TGR5/ mice fed with a high fat diet display
impaired insulin sensitivity, which is in agreement with our ﬁnd-
ings. Other evidence that TGR5 activation is beneﬁcial with
regard to diabetes comes from the observation that the triterpe-
noid, oleanolic acid, a natural TGR5 agonist, also improves glu-
cose homeostasis [81].
TGR5 modulates the immune response
One of the initial studies on TGR5 concerns its role in immune
cells and has linked TGR5 to the immunomodulatory properties
of BAs [62]. This action of TGR5 is very relevant, as low-grade
inﬂammation is suggested to contribute to the development of
the metabolic syndrome [82]. TGR5 is highly expressed in mono-
cytes and macrophages, an observation derived from the ﬁnding
that TGR5 expression is present in human spleen and human
CD14+ monocytes, as well as in rabbit alveolar macrophages
[62,68]. In accordance with a report that cAMP inhibits LPS-
induced cytokine secretion [83], BAs capable of activating TGR5
were found to increase cAMP production in alveolar macrophages
[62]. In addition, BAs reduce the phagocytic activity of these cells
and inhibit LPS-induced production of several pro-inﬂammatory
cytokines such as tumor necrosis factor-a (TNF-a), Interleukin
(IL)-1a, IL-1b, IL-6, and IL-8 [62]. Human monocytic leukemia
THP-1 cells transfected with TGR5 exhibit increased cAMP pro-
duction and a reduction in LPS-induced TNF-a expression. These
effects were not observed in untransfected THP-1 cells, which
express low levels of TGR5, demonstrating that these effects of
bile acids are mediated through activation of TGR5 [62]. Further-
more, stimulation of isolated rat Kuppfer cells with taurolitho-
cholic acid (TLC) or other TGR5 agonists, such as oleanolic acid,
as well as cAMP stimulation resulted in reduced expression of
IL-1a, IL-1b, IL-6, and TNF-a following LPS treatment [68].
Although the inhibition of inﬂammation through TGR5 activation
can be considered beneﬁcial for atherosclerosis, steatosis, and
obesity, the anti-inﬂammatory action of TGR5 in macrophages
might perhaps also explain observations that obstructive cholan-
gitis is associated with enhanced susceptibility for infections due
to decreased clearance of intrabiliary bacteria [84]. Recently,
association of 22 single nucleotide polymorphisms (SNPs) within
the TGR5 genes were assessed with regard to primary sclerosing
cholangitis (PSC). A weak association of one of these SNPs,
rs11554825, was observed with PSC as well as with ulcerative
colitis, although it could not be excluded that SNPs in neighbor-
ing genes that are in linkage disequilibrium with rs11554825
are responsible for this effect [85].
TGR5 in liver function
Administration of the speciﬁc TGR5 agonist, INT-777 to high fat
diet-fed mice reduces liver steatosis and associated hepatocyte
damage, as measured by plasma liver enzymes LDH, ASAT, and
ALAT [71]. This is correlated with decreased plasma triglyceride
and nonesteriﬁed fatty acid levels. The latter is consistent with
the report by Vassileva et al. showing a pronounced hepatostea-
tosis in male TGR5/ mice fed a high fat diet for 8 weeks [72].
These data suggest that activation of TGR5 may prevent non-
alcoholic fatty liver disease (NAFLD), although the precise regula-
tory mechanisms by which TGR5 induces this effect on liver
triglycerides remains to be dissected. Although TGR5 seems not1268 Journal of Hepatology 2011expressed in hepatocytes, it is detected in many cell types of
the liver where it could directly or indirectly modulate liver func-
tion and triglyceride metabolism. TGR5 is for instance highly
expressed in Kupffer cells, which are resident liver macrophages
[68]. It has become clear that these cells, together with their pro-
inﬂammatory cytokine secretion, are critically involved in the
progression of NAFLD [86]. The anti-inﬂammatory action of
TGR5 in these cells could, therefore, contribute to the protective
effects of TGR5 on steatosis. TGR5 has also been shown to mod-
ulate microcirculation and ﬂuid secretion in the endothelial and
biliary epithelial cells of the liver [67,74]. Although the increased
energy expenditure and GLP-1 secretion following TGR5 activa-
tion may very well explain the signiﬁcant improvement in liver
steatosis, it will be challenging to examine whether any of these
other cell types in the liver contribute to the protective effects of
TGR5 activation against steatosis. Cell-type speciﬁc TGR5/
mouse models will be extremely valuable tools to address these
questions.BA signaling as a target for intervention in the metabolic
syndrome
BA signaling as target for intervention
The signiﬁcance of BAs in human triglyceride metabolism is
underlined by ﬁndings that bile-acid binding resins induce the
production of VLDL and that treatment of cholesterol gallstones
in humans with CDCA reduces hypertriglyceridemia [87–89]. In
addition to the effects of BAs on human triglyceride metabolism,
BAs are correlated to increased insulin sensitivity in humans [76].
Furthermore, patients after bariatric surgery to correct for obesity
have higher circulating levels of BAs, which are positively corre-
lated to peak GLP-1 levels [77]. The latter observation was
recently conﬁrmed in obese patients, who have a decreased post-
prandial BA response and suboptimal GLP-1 secretion in compar-
ison to normal weight subjects [90].
A few studies report on the positive effects of bile-acid binding
resins on glucose homeostasis [91–93]. The positive effects of bile
acid sequestrants on glucose homeostasis could be the conse-
quence of improved general metabolism subsequent to the elim-
ination of cholesterol. It might, however, also raise the intriguing
possibilities that bile-acid binding resins through still unknown
mechanisms trigger TGR5 activation and GLP-1 secretion, hence
contributing to the beneﬁcial effects on glucose homeostasis.
The biological properties of TGR5 described in this review (see
Table 1), mostly observed in animal models, strongly indicate
that TGR5 is linked to the beneﬁcial properties of BAs in humans.
This is underlined by the ﬁndings that the improvements of BAs
on metabolic homeostasis are among others linked to GLP-1, for
which its regulation by TGR5 is well documented [71,79]. Fur-
thermore, a recent human genetic study indicates a potential
association of TGR5 with some aspects of the metabolic syn-
drome. This study addressed the link between the single nucleo-
tide polymorphism (SNP) rs3731859 within the human TGR5
gene and the risk for type 2 diabetes [94]. Although no correlation
was found between the onset of diabetes and the investigated
SNP, nominal associations with body mass index, waist circum-
ference, intramyocellular lipids, and fasting GLP-1 levels were
identiﬁed. This interesting result warrants further studies to
explore the effect of this (and other) SNPs in the TGR5 gene invol. 54 j 1263–1272
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different populations and calls for further mechanistic studies
that address whether this SNP, located at the 50-untranslated
region, inﬂuences TGR5 expression levels.
Pharmacological targeting of TGR5
BAs bind and activate both TGR5, as well as other (nuclear) recep-
tors, among which is FXR. The binding pocket for the membrane
BA receptor TGR5 and the nuclear BA receptor FXRa is only par-
tially conserved and minor structural modiﬁcations on the ste-
roid side chain of BAs can dictate selectivity of the ligand
toward TGR5 [95,96]. This unique ligand-binding pocket of
TGR5, therefore, allows the design of receptor selective ligands,
leading to drugs that are able to target TGR5 exclusively.
TGR5 may be targeted by natural compounds as well as by
synthetic agonists. Such TGR5 agonists include natural BAs,
semi-synthetic BAs, such as 6-ethyl-23(S)methyl-cholic acid
[97], bile alcohols, and triterpenoid compounds of plant origin,
such as oleanolic acid and betulinic acid [81,98–100]. Also certain
steroid hormones potently activate TGR5 [98], an observation
that has been recently conﬁrmed [101]. Signiﬁcant progress has
also been made with the search for synthetic TGR5 agonists, as
3-aryl-4-isoxazolecarboxamides were recently identiﬁed to acti-
vate TGR5, and found to induce GLP-1 secretion in canines
[102]. Also speciﬁc 2-aryl-3-aminomethylquinones were recently
identiﬁed as TGR5 agonists and observed to induce GLP-1 secre-
tion and to improve glucose homeostasis in diet-induced obese
mice [63]. Furthermore, many drug companies have active
TGR5 programs, which have already resulted in the publication
of several patents that describe additional TGR5 compounds. Fur-
ther biological studies using these novel selective and potent syn-
thetic TGR5 agonists are clearly awaited. Studies in animal
models with tissue-speciﬁc deﬁciencies in TGR5 and this steadily
increasing battery of TGR5 agonists will result in a better under-
standing of TGR5 biology and pharmacology, and perhaps new
treatment options for different aspects of the metabolic
syndrome.
Not all that shines is gold – issues with TGR5
Recently several properties of TGR5 have been described, that
require further investigation as they could potentially underlie
some side effects. For example, in cell culture models TGR5 has
also been linked to epidermal growth factor receptor (EGFR)
and c-Jun N-terminal kinase (JNK) signaling pathways, which
modulate cell proliferation and apoptosis [103,104]. This may
suggest that TGR5 has a potential role in cancer development,
but unfortunately evidence of such an effect was only ascertained
in cultured cells and further studies in vivo are deﬁnitely required
[103,104]. TGR5 agonists, including certain steroids [98], were
also reported to stimulate the generation of reactive oxygen spe-
cies in cultured astrocytes [101]. The impact of this potential lia-
bility also requires further investigation in vivo. TGR5 activation
has been suggested to inﬂuence cardiomyocytes as the TGR5-
active bile acids tauro-CDCA and LCA activated AKT and inhibited
glycogen synthase kinase-3b in these cells [105]. In view of the
pleiotropic effects of BAs, it will be of interest to assess
these effects in TGR5/ mice. In addition to these cellular
observations, it has been reported that TGR5/ mice have
reduced pancreatitis upon direct exposure of the pancreas to high
concentrations of taurolithocholic acid 3-sulfate sodium saltJournal of Hepatology 2011(TLCS) [106]. In this study, the fact that the pancreas is exposed
to very high concentrations of TLCS, which are normally never
reached even under pathological conditions, may raise questions
about its physiological relevance. Finally, the fact that TGR5/
mice were protected against cholelithiasis [64] could imply that
TGR5 agonism predisposes to this condition; there are, however,
no data to support a negative effect of TGR5 agonists on choleli-
thiasis. It needs to be stressed that many of these potential
unwanted side effects were either observed in cultured cells or
in animal models where extremely high, non-physiological con-
centrations of BAs were used. Further detailed studies using con-
ditions closer to physiology are, therefore, necessary to evaluate
whether such effects are also relevant for the clinical setting.
Conclusions and future perspectives
The metabolic studies described above suggest that targeting
TGR5 could provide an exciting new therapeutic approach to
improve several aspects of the metabolic syndrome. Multiple
studies reveal that TGR5 has beneﬁcial effects on body weight
in high-fat diet-fed mice. In addition, TGR5 activation improves
glucose homeostasis and reduces hepatic steatosis. Also beneﬁ-
cial effects of TGR5 on macrophage-driven inﬂammation, as evi-
denced by the reduction of pro-inﬂammatory cytokines, may
contribute to a potential positive effect of TGR5 with regard to
the metabolic syndrome. These properties of TGR5 clearly sug-
gest that activation of this membrane receptor is valuable to
combat multiple aspects of the metabolic syndrome in humans.
In view of the established role of BA or BA like molecules (dafa-
chronic acids) to promote longevity in yeast [52] and in the
worm Caenorhabditis elegans [107,108], it is furthermore plausi-
ble that the various strategies to modulate BA-signaling
described in this review could increase lifespan through their
potent hormonal activities that improve metabolism and reduce
inﬂammation, two important contributors that determine
healthspan [109].
The development of several novel natural, semi-synthetic, and
synthetic TGR5 agonists is likely to further advance this receptor
as a target for the metabolic syndrome. In addition, localized or
tissue-speciﬁc gene targeting will shed light on ways to increase
the efﬁcacy and speciﬁcity of drugs that target this BA receptor.
Despite the fact that we are convinced that targeting BA signaling
pathways through TGR5 holds great promise for the treatment of
metabolic diseases, still much work needs to be done, especially
to make sure that such compounds are safe.Disclosure
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